Detalhe da pesquisa
1.
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
PLoS Pathog
; 18(10): e1010882, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36191037
2.
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
Br J Haematol
; 194(6): 999-1006, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34085278
3.
BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes.
Haematologica
; 107(5): 1181-1184, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045695
4.
Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection.
mBio
; 14(5): e0120623, 2023 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37747187
5.
Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.
mBio
; 13(2): e0379821, 2022 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35297676
6.
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
Cell Rep
; 39(5): 110757, 2022 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477023
7.
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.
Cancer Res Commun
; 2(11): 1449-1461, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36824220
8.
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
Lancet Rheumatol
; 4(1): e42-e52, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34778846
9.
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.
Lancet Rheumatol
; 3(9): e627-e637, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34258590
10.
Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.
medRxiv
; 2021 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34127977
11.
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Nat Microbiol
; 6(11): 1433-1442, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34654917
12.
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.
Blood Adv
; 7(10): 1954-1957, 2023 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36083126
13.
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Blood Cancer J
; 12(4): 73, 2022 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459222
14.
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.
Leukemia
; 35(12): 3573-3577, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023850
15.
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Cancer Cell
; 39(12): 1654, 2021 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906318
16.
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Cancer Cell
; 39(11): 1448-1449, 2021 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34717827
17.
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
Cancer Cell
; 39(11): 1445-1447, 2021 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34678151